Finanzas de Medifast Inc (MED)MEDMedifast Inc

Medifast Inc (MED) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Take Shape For Life, accounting for 88.0% of total sales, equivalent to $68.61M. Other significant revenue streams include Medifast and Medifast Weight Control Centers- Franchise. Understanding this composition is critical for investors evaluating how MED navigates market cycles within the Food Processing industry.

Evaluating the bottom line, Medifast Inc maintains a gross margin of 69.45%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -26.87%, while the net margin is -24.30%. These profitability ratios, combined with a Return on Equity (ROE) of -20.69%, provide a clear picture of how effectively MED converts its operational activities into shareholder value.

In the context of the broader market, MED competes directly with industry leaders such as EGG and ATOM. With a market capitalization of $142.32M, it holds a significant position in the sector. When comparing efficiency, MED's gross margin of 69.45% stands against EGG's -1.13% and ATOM's N/A. Such benchmarking helps identify whether Medifast Inc is trading at a premium or discount relative to its financial performance.

Medifast's total revenue has been declining, with Q2 2026 revenue at $76.4 million, but it exceeded expectations, indicating some operational stability. However, net income has been negative for several quarters, with a notable loss of $17.5 million in Q3 2026, raising red flags about profitability.